Loading...

ASLAN Pharmaceuticals Limited

ASLN•NASDAQ
Healthcare
Biotechnology
$0.60
$-0.10(-14.27%)

ASLAN Pharmaceuticals Limited (ASLN) Stock Overview

Explore ASLAN Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.3/100

Key Financials

Market Cap1.7M
P/E Ratio-0.01
EPS (TTM)$-16.00
ROE17.97%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.64

ASLN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ASLAN Pharmaceuticals Limited (ASLN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.64.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.01 and a market capitalization of 1.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ASLNStats details for ASLN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ASLNAnalyst Recommendations details for ASLN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

CEO

Carl Alan Jason Morton Firth EMBA,

Employees

35

Headquarters

83 Clemenceau Avenue, Singapore

Founded

2018

Frequently Asked Questions

;